Literature DB >> 26022563

Valuing vaccines: deficiencies and remedies.

David E Bloom1.   

Abstract

Current evaluation models for the value of vaccines typically account for a small subset of the full social and economic benefits of vaccination. Health investments yield positive economic benefits via several channels at the household, community, and national levels. Underestimating, or worse, not considering these benefits can lead to ill-founded recommendations regarding the introduction of vaccines into immunization programs. The clear and strong links between health and wealth suggest the need to redesign valuation frameworks for vaccination so that the full costs may be properly weighed against the full benefits of vaccines.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Keywords:  Benefit–cost analysis; Cost-effectiveness analysis; Valuation

Mesh:

Substances:

Year:  2015        PMID: 26022563     DOI: 10.1016/j.vaccine.2015.03.023

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  The Value(s) of Vaccination: Building the Scientific Evidence According to a Value-Based Healthcare Approach.

Authors:  Giovanna Elisa Calabro'; Elettra Carini; Alessia Tognetto; Irene Giacchetta; Ester Bonanno; Marco Mariani; Walter Ricciardi; Chiara de Waure
Journal:  Front Public Health       Date:  2022-03-09

2.  [Innovations in vaccinology: challenge and opportunities for Africa].

Authors:  Doudou Diop; Melvin Sanicas
Journal:  Pan Afr Med J       Date:  2017-04-25

3.  Simultaneously characterizing the comparative economics of routine female adolescent nonavalent human papillomavirus (HPV) vaccination and assortativity of sexual mixing in Hong Kong Chinese: a modeling analysis.

Authors:  Horace C W Choi; Mark Jit; Gabriel M Leung; Kwok-Leung Tsui; Joseph T Wu
Journal:  BMC Med       Date:  2018-08-17       Impact factor: 8.775

4.  Realising the broader value of vaccines in the UK.

Authors:  Simon Brassel; Margherita Neri; Phill O'Neill; Lotte Steuten
Journal:  Vaccine X       Date:  2021-04-06

5.  The contribution of microbial biotechnology to economic growth and employment creation.

Authors:  Kenneth Timmis; Victor de Lorenzo; Willy Verstraete; Juan Luis Ramos; Antoine Danchin; Harald Brüssow; Brajesh K Singh; James Kenneth Timmis
Journal:  Microb Biotechnol       Date:  2017-09-04       Impact factor: 5.813

6.  MCDA from a health economics perspective: opportunities and pitfalls of extending economic evaluation to incorporate broader outcomes.

Authors:  Mark Jit
Journal:  Cost Eff Resour Alloc       Date:  2018-11-09

7.  Micro-planning for immunization in Kaduna State, Nigeria: Lessons learnt, 2017.

Authors:  Gregory C Umeh; Dauda M Madubu; Charles Korir; Nkwogu Loveday; Sambo Ishaku; Hadiza Iyal; Semeeh A Omoleke; Terna I Nomhwange; Atiku Aliyu; Audu Musa; Raymond Dankoli; Adamu Mi Ningi; Fiona Braka; Paul M Dogo; Haliru Soba; Neyu Iliyasu
Journal:  Vaccine       Date:  2018-10-23       Impact factor: 3.641

8.  The COVID-19 pandemic: some lessons learned about crisis preparedness and management, and the need for international benchmarking to reduce deficits.

Authors:  Kenneth Timmis; Harald Brüssow
Journal:  Environ Microbiol       Date:  2020-05-03       Impact factor: 5.476

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.